Jeffrey L. Saver, M.D., Mayank Goyal, M.D., Alain Bonafe, M.D., Hans-Christoph Diener, M.D., Ph.D., Elad I. Levy, M.D., Vitor M. Pereira, M.D., Gregory W. Albers, M.D., Christophe Cognard, M.D., David J. Cohen, M.D., Werner Hacke, M.D., Ph.D., Olav Jansen, M.D., Ph.D., Tudor G. Jovin, M.D., Heinrich P. Mattle, M.D., Raul G. Nogueira, M.D., Adnan H. Siddiqui, M.D., Ph.D., Dileep R. Yavagal, M.D., Blaise W. Baxter, M.D., Thomas G. Devlin, M.D., Ph.D., Demetrius K. Lopes, M.D., Vivek K. Reddy, M.D., Richard du Mesnil de Rochemont, M.D., Oliver C.Forty-six of the 123 subjects had obtainable prediagnostic cryopreserved whole bloodstream. For one subject, the stored bloodstream contained an insufficient amount of cells for our analysis. Therefore, 45 topics with CLL were eligible for our research. For all subjects, a blood sample have been acquired at least 3 months before the date of diagnosis. We also included 10 subjects without a CLL diagnosis as negative controls. Topics in the screening group of the PLCO Cancers Screening Trial had undergone screening for the detection of prostate cancer , lung cancer , colorectal malignancy , and ovarian tumor . Subjects who provided annual blood samples for 6 years for the PSA test or CA-125 were also asked to contribute extra blood samples for study on cancer and other diseases common with their age group.